BTK Inhibitors as Sensitizing Agents in Solid Tumors | Agenda Bookshop Skip to content
Please note that books with a 10-20 working days delivery time will not arrive before Christmas.
Please note that books with a 10-20 working days delivery time will not arrive before Christmas.
Age Group_Uncategorized
Age Group_Uncategorized
automatic-update
B01=Al-Ola A. Abdallah
B01=Robert Dreicer
B01=Varinder Kaur
Category1=Non-Fiction
Category=KJT
Category=MJCL
Category=MQW
Category=PS
Category=UFL
Category=UYM
COP=United Kingdom
Delivery_Pre-order
Language_English
PA=Not yet available
Price_€100 and above
PS=Forthcoming
softlaunch

BTK Inhibitors as Sensitizing Agents in Solid Tumors

English

BTK Inhibitors as Sensitizing Agents in Solid Tumors provides a thorough review of mechanisms of multi-drug resistance in cancers, describing, in detail, the mechanisms, current studies and future directions of the role of BTK inhibitors in overcoming therapy resistance in cancer, including resistance to chemotherapy, targeted therapies and immunotherapy. The book discusses topics such as mechanisms of therapy resistance in cancer cells, BTK inhibitors in paclitaxel, docetaxel, platinum, BRAF and radio resistance. In addition, the book discusses ibrutinib and its role in immunotherapy resistance, novel BTK inhibitors and future perspectives. This book is a valuable resource for cancer researchers, oncologists, graduate students, and members of the biomedical field who are interested in the potential of BTK inhibitors as sensitizing agent to resistant cancers. See more
Current price €134.09
Original price €148.99
Save 10%
Age Group_Uncategorizedautomatic-updateB01=Al-Ola A. AbdallahB01=Robert DreicerB01=Varinder KaurCategory1=Non-FictionCategory=KJTCategory=MJCLCategory=MQWCategory=PSCategory=UFLCategory=UYMCOP=United KingdomDelivery_Pre-orderLanguage_EnglishPA=Not yet availablePrice_€100 and abovePS=Forthcomingsoftlaunch

Will deliver when available. Publication date 01 Sep 2024

Product Details
  • Dimensions: 191 x 235mm
  • Publication Date: 01 Sep 2024
  • Publisher: Elsevier Science & Technology
  • Publication City/Country: United Kingdom
  • Language: English
  • ISBN13: 9780323952392

About

Robert Dreicer MD MS FASCO MACP received his medical degree from the University of Texas-Houston and a Master of Science from the University of Texas Graduate School of Biomedical Sciences. Following his oncology fellowship he joined the faculty at University of Iowa achieving tenure and serving as the associate director of the division of haematology/oncology. He was recruited to Cleveland Clinic where he served as chair of the department of solid tumor oncology from 2006-2014 before joining UVA Cancer Center in 2015. His research interests are in novel therapeutic approaches for urologic cancer including prostate urothelial and kidney cancers. He serves as member of the Medical Oncology Test Writing Committee of the American Board of Internal Medicine and is member of the editorial board of New England Journal of Medicine's Journal Watch Hematology/Oncology. Dreicer has been named for many years to Top Doctors in America Americas Best Doctors and Americas Top Doctors for Cancer. Dr Varinder Kaur MD FACP has expertise in haematology and medical oncology including clinical application of ibrutinib in its varied roles. She is a clinical trialist at University of Virginia with particular focus on melanoma and head-neck cancers immune-oncology and vaccine trials. She has authored several high-quality publications including with rare side effects and resistance mechanisms for ibrutinib. She mentors clinical fellows and residents. She is a member of scientific review committee of Oncology Research Information Exchange Network and has reviewed grant applications for the same. She has served as a member for American Society of Clinical Oncology Systemic Therapy guidelines for melanoma committee and ASCO/ABIM test material development subcommittee as well as a member of ASCO Education Book Review Panel. Dr. Al-Ola Abdallah MD is currently Assistant Professor of Medicine and the director of the Plasma Cell Disorder Clinic for the Division of Hematological Malignancies and Cellular Therapy (HMCT). Recently he was also appointed as the Educational Medical Director for the Division. Dr. Abdallah currently works as principal investigator on many investigator-initiated and pharmaceutical-sponsored clinical trials. His research interests include multiple myeloma smoldering myeloma amyloidosis immunotherapy and CAR-T cell for myeloma and CLL with a focus on improving patient outcomes specifically patients with high-risk subsets of plasma cell dyscrasias and health- related quality of life in myeloma patients.

Customer Reviews

Be the first to write a review
0%
(0)
0%
(0)
0%
(0)
0%
(0)
0%
(0)
We use cookies to ensure that we give you the best experience on our website. If you continue we'll assume that you are understand this. Learn more
Accept